This article was originally posted on Docwire News.
DocWire News sat down with Saad Usmani, M.D., MBA, FACP to discuss an indirect treatment comparison study which assesses DARZALEX® (daratumumab) Plus Lenalidomide and Dexamethasone (D-Rd) and Bortezomib-Containing Regimens in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma.